Study objective -To estimate age dependent sensitivity and sojourn time in a breast cancer screening programme by different methods. Population and methods -The study population comprised women participating in the DOM project -the Utrecht screening programme for the early detection of breast cancer. Breast cancer screening prevalence data and incidence rates after a negative screen were used to estimate age specific sensitivity and mean sojourn time by different methods. Main results -Maximum likelihood estimates of the mean sojourn time varied from one year for women aged 40-49 years to three years for women over the age of 54. Sensitivity was calculated by two different methods. Both pointed to a high sensitivity (around 100%) in the age groups 40-49 and over 55 years. For women aged 50-54, the sensitivity varied from 63% to 100%, depending on the method used and the value of the baseline incidence rate. Conclusions -Different methods of estimating sensitivity pointed at an acceptable level in women over and under 50 years ofage. Sojourn time, and thus the tumour growth rate, seemed to be age dependent. This could mean that the until now disappointing screening results in women under 50 years of age are not so much a result of low sensitivity as of a relatively high tumour growth rate in younger women.
Mammographic screening for breast cancer has been accepted as beneficial in women over 50 years of age.' Until now, however, screening results in women under 50 years have been generally disappointing.2" Only the Health Insurance Plan study showed a delayed effect on mortality after eight years of follow up. 5 The recently published overview of the five Swedish trials also showed a (non-significant) mortality reduction, again only after eight years of follow up. 6 Reasons for the delay or even absence of benefit in these young women has been sought in either a low sensitivity of mammography or a high tumour growth rate in young women, which implicates a short sojourn time. '7-1 There are several ways of estimating sensitivity. In a previous publication we used the so called classic method -the proportion of all cancers detected within a certain time after screening in relation to those detected at screening. This estimate was used in women under and over the age of 50 for various time intervals after screening. In this way we found indications that the reason for the disappointing screening results in women under 50 years of age was not so much a low sensitivity as a relatively high tumour growth rate in this age group.'2 The validity ofthis method is uncertain as it is not possible to distinguish truly false negative cases from cases with a short preclinical phase that had not begun at the time of screening. Furthermore, this estimate is affected by the inclusion of cases with indefinitely long lead times. Alternative methods of estimating sensitivity have been derived that deal with these issues.
In the current study two of these methods are used to The length of time by which diagnosis is advanced in a screening programme depends both on the length of time the disease is in the preclinical detectable phase (the sojourn time) and the probability that the disease is detected by the screening test (sensitivity). Both parameters (mean sojourn time and sensitivity) were estimated simultaneously by a statistical method described by Day and Walter.'316 In their method, the incidence after a negative screen and the prevalence at each screening are expressed in terms of the sensitivity, probability distribution of the sojourn time (assumed to be negative exponential), and the baseline incidence rate in the absence of screening. From data on the number of cases found at each screen and the number of cases diagnosed between screens, the false negative rate (1 minus the sensitivity) and mean sojourn time are estimated by maximisation of the log likelihood. A joint confidence interval can be constructed for both parameters.
Although the baseline incidence can also be estimated by the model, Day and Walter suggest that this parameter is fixed, for instance by cancer registry data. In our analyses, both approaches were used. A disadvantage of the above mentioned model is the use ofprevalence data. As Walter and Day pointed out, these include cases that might take years to surface, or never surface at all. 16 The model proposed by Day in 1985 requires incidence data only and the probability distribution of the sojourn time. "4 Using his model and the estimate of the mean sojourn time from the previous model, sensitivity has been adjusted as follows:
in which S is the sensitivity, IT is the incidence in time T after the first screen, I is the baseline incidence in the absence of screening. The integral in the denominator is the proportion of cases with a sojourn time of duration less than time T. In this formula, F(t) is taken as the exponential distribution of the sojourn time with mean (X) estimated from the model of Day and Walter: [1 -exp(-Xt)]. " Both methods were appled to three different age groups -40-49, 50-54, and >54 years.
Results Table 1 shows the age specific numbers of women screened, prevalence rates, and the expected incidence rate in the absence of screening. As expected, the prevalence rate increased with age as did the ratio of the prevalence rate to the expected incidence rate. Table 2 gives the age specific incidence rates per year after screening. In the last column these rates were divided by the expected incidence rates (see table 1 ) to obtain the proportion of expected cases in the absence of screening. This shows that in the age group 40-49 the incidence rate is back on the prescreening level within two years, while this takes three years in women over the age of 50. In the second model, baseline incidence as well as sensitivity and mean sojourn time were estimated. For the two youngest age groups (40-49 and 50-54), the baseline incidence rate estimated from the model was higher than the rates based on cancer registry data. Consequently, the estimates for the mean sojourn time were lower than in the previous model. Maximum likelihood estimates for sensitivity in both age groups are 100%, but again the confidence intervals for both variables are wide, especially in the age group 40-49. As can be derived from the goodness of fit x2 value in the last row, the second model fits the data better than the first.
In In contrast to our expectations, no negative association between sensitivity and age was seen. We found a high sensitivity both in women under the age of 50 and over the age of 55, and an indication of a lower sensitivity in women aged 50-54.
The estimate of 100% sensitivity in the age group 40-49 years should be interpreted with caution as numbers were small and confidence intervals were therefore wide, especially in this age group. However, both methods used to calculate sensitivity in this study point in the same direction. Furthermore, these results are in line with those of our previous study. Here, age specific sensitivity was estimated by the "classic" method using time intervals varying from 6 months to 2 years.'2 Our results are not in agreement with other studies which found a low sensitivity in women under the age of 50. Sometimes sensitivity is calculated in the classic way using a 1 or even 2 year interval, which seems improbable in the light of a mean sojourn time of 1 year.1920 Results from the Nijmegen screening programme, calculating age specific estimates of sensitivity using different methods, also show an acceptable sensitivity in women under 50 years of age.'0 Finally, the underlying assumptions of the model, such as a negative exponential distribution of the sojourn time, could hold better for older than for younger women.
In essence, the general conclusions of this study remained the same, whether using externally fixed or estimated baseline incidence rates. Tumour growth rate is age dependent and varied from 1 year in women under 50 years of age to 3 years in women over 55. Age specific sensitivity as estimated by two different methods pointed at an acceptable sensitivity both in women over and under the age of 50. This suggests -that the most important cause of the current disappointing screening results in women under the age of 50 might be a higher tumour growth rate at a young age.
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